MétaCan
ENFR
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

Export CSVExport JSONAPI query

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Topic
Prostate Cancer Treatment and Research
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

3,880 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
3,880 works in the cohort · of 4,299,418page 31 of 78

Labels cover 13 of 3,880 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 3,880 of 3,880 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affno abstractunlabeled
Prostate Cancer Genomic Subtypes
Michael Fraser, Alexandre Rouette
2019· review· en· Advances in experimental medicine and biology· Medicine
machine prediction:candidate · noneconsensus · none
11
citations
affaboutunlabeled
Trends in Hormonal Management of Prostate Cancer:
Susan J. Bondy, Neill Iscoe, Deanna M. Rothwell, Elaine H. Gort, Neil Fleshner, Lawrence Paszat +1 more
2001· article· en· Medical Care· Medicine
machine prediction:candidate · noneconsensus · none
11
citations
affno abstractunlabeled
Imaging in Prostate Carcinoma
Katherine Zukotynski, Masoom A. Haider
2013· review· en· Hematology/Oncology Clinics of North America· Medicine
machine prediction:candidate · noneconsensus · none
10
citations
afffundunlabeled
A polygenic two-hit hypothesis for prostate cancer
Kathleen E. Houlahan, Julie Livingstone, Natalie S. Fox, Natalie J. Kurganovs, Helen He Zhu, Jocelyn Sietsma Penington +14 more
2023· article· en· JNCI Journal of the National Cancer Institute· Medicine
machine prediction:candidate · noneconsensus · none
10
citations
affunlabeled
PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients (pts) with localized or locally advanced high-risk prostate cancer (PC).
Adam S. Kibel, Martin Gleave, Sabine Brookman‐May, Won Bae Kim, Christopher P. Evans, Eleni Efstathiou +13 more
2022· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
10
citations
affunlabeled
Overall survival (OS) in patients (Pts) with diagnostic positive (Dx+) breast cancer: Subgroup analysis from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in AR+ triple-negative breast cancer (TNBC) treated with 0-1 prior lines of therapy.
Tiffany A. Traina, Denise A. Yardley, Lee S. Schwartzberg, Joyce O’Shaughnessy, Javier Cortés, Ahmad Awada +14 more
2017· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
10
citations
← previousnext →

How this was built: Screen · Findings · About